M&A / Deals Roche places a $1bn bet on C4T degrader-antibody conjugates PharmaphorumRoche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.M&A / DealsOncologyRead full story pharminent April 10, 2026 (Last updated: April 10, 2026) Pharmaphorum Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T. M&A / DealsOncologyRead full story Post navigation Previous: Roche and C4 Therapeutics to advance degrader-antibody conjugates researchNext: GSK again pulls application for leucovorin, touted by FDA as potential autism treatment Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
